Bespoke to Scalable: AI-Driven Engagement in Innovative Medicines
As cell and gene therapies (CGTs) continue to revolutionise treatment for cancer and rare diseases, the industry grapples with challenges surrounding development costs and limited patient access. AI is emerging as a transformative force, streamlining operations, accelerating diagnosis and enabling dynamic, personalised engagement with patients and providers.
Download this latest paper to unlock real-world applications   >>>
Key learnings and takeaways include:

  • AI-Powered Orchestration: Discover how AI is managing CGT logistics from complex supply chains to real-time scheduling.
  • Empowering Field Teams: Learn how AI-generated insights are transforming field teams into strategic partners who build trust and navigate complexity.
  • Human-AI Collaboration: Understand why combining AI with human empathy is key to unlocking competitive advantage in CGT.
  • Expert Perspectives: Hear from pharma leaders, like Caspar Gøtsche, Global Medical Director, Cell and Gene Therapy, Bayer surrounding the positive uptake of AI: “In my world, there’s little fear of AI; what I see instead is curiosity and a real desire to improve the technology by using it”
Don’t miss this latest read, download now to discover how AI is driving scalable personalisation in CGT and why staying ahead is crucial >>>
Many thanks,
Emma Haslam
Global Project Director
Pharma
Reuters Events
Download your whitepaper here 
With industry commentary from senior leaders at AstraZeneca, Bayer, Novartis and Cognizant
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: https://www.thomsonreuters.com/en/privacy-statement.html.
Please tick this box to give Reuters Events permission to provide my contact information to Cognizant - https://www.cognizant.com/uk/en- so Cognizant news and offers with me by email or telephone.
You may unsubscribe from receiving news and offers from the sender at any time by following the instructions in the communications received. Cognizant handles your information as described in the Cognizant Privacy Notice -https://www.cognizant.com/us/en/privacy-notice
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.